Thermo Fisher: Valuation Compression and High Leverage Raise Concerns

Key Facts

1TMO is trading at 20-21x earnings.

2Net leverage stands at 3.5x.

3A recent microbiology business sale at a low multiple will dilute EPS.

Amid pressure on healthcare stocks, Thermo Fisher Scientific (TMO) faces increased scrutiny from analysts. According to a Seeking Alpha analysis, the stock is trading at 20-21x earnings, while net leverage stands at 3.5x. The analysis also notes that a recent microbiology business sale at a low multiple will dilute earnings per share.

This assessment comes as TMO shares closed at $513.03 on June 26, with a daily range of $499.56 to $514.80, reflecting limited volatility. Market data suggests the stock trades below its historical valuation multiples, but elevated leverage and modest organic growth weigh on its appeal.

At the latest close, the stock is at $513.03, with investors awaiting next-quarter results to gauge organic growth trends and the company's ability to reduce leverage. Focus will also remain on any management updates regarding capital allocation and share buyback plans.